Manzo Pharmaceuticals, Inc. engages in the provision of pharmaceutical preparations services. The company is headquartered in North York, Ontario. The company went IPO on 2001-07-11. The firm also develops its lactose intolerance product, for which it holds an exclusive patent license. The firm's primary products are dietary supplements, probiotics and natural remedies. The firm's subsidiary, Manzo Pharmaceuticals LLC (Manzo), is an alternative healthcare company with patents for a probiotic remedy for lactose intolerance. The firm also owns other products, including a remedy for babies suffering from colic and/or digestive gas. Manzo's Lacto-Freedom probiotic is a probiotic that aids in the digestion of lactose-containing foods, designed specifically for people with lactose sensitivity.
MNZO stock price ended at $0 on 火曜日, after rising NaN%
On the latest trading day Apr 21, 2026, the stock price of MNZO rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 499.1K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 501.9K shares were traded, equating to a market value of approximately --.